Medicare Part D ‘Enhanced’ MTM Model: Not Much To Show After Three Years?
Medication therapy management program has not produced savings in Medicare spending on medical services or a significant, consistent benefit on improving adherence or reducing hospitalizations, report finds.
You may also be interested in...
A proposed “enhanced” model for Medication Therapy Management in Medicare Part D draws rave reviews from a House subcommittee. The prospect of using medication better to lower overall costs is a great counterpoint to headlines about excessive drug prices.
340B Hospitals Charging Private Insurers Nearly Four Times Acquisition Costs On Cancer Drugs – Study
New report makes a case for further scrutiny of the 340B program's contributions to high drug costs, although manufacturers remain the main target of legislative and regulatory reform proposals.
Medicare Price Negotiation Targeting Only Post-Exclusivity Drugs Proposed By Moderate House Democrats
Legislation authorizing the US government to directly negotiate drug prices with manufacturers failed to pass in one key House committee as a trio of Democrats joined Republicans to vote against advancing the policy.